Capricor Therapeutics (NASDAQ:CAPR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday. The firm currently has a $2.00 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price indicates a potential upside of 6.38% from the stock’s current price.
According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “
Separately, HC Wainwright restated a “buy” rating and issued a $8.60 price objective (up from $6.50) on shares of Capricor Therapeutics in a report on Friday, January 26th.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Brown Advisory Inc. bought a new stake in shares of Capricor Therapeutics in the 4th quarter worth approximately $1,796,000. Belpointe Asset Management LLC bought a new stake in shares of Capricor Therapeutics in the 3rd quarter worth approximately $249,000. Jane Street Group LLC bought a new stake in shares of Capricor Therapeutics in the 3rd quarter worth approximately $190,000. Finally, Wells Fargo & Company MN bought a new stake in shares of Capricor Therapeutics in the 3rd quarter worth approximately $107,000. Hedge funds and other institutional investors own 9.46% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/03/12/capricor-therapeutics-capr-upgraded-to-buy-by-zacks-investment-research.html.
Capricor Therapeutics Company Profile
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.